OpenAlex
PricingAboutJobs
Log inGet started
Author

Howard Chan

Institution: Calvary Mater Newcastle Hospital
Observed institution: Calvary Mater Newcastle Hospital
ORCID: 0000-0002-5802-5230
Observed ORCID: 0000-0002-5802-5230
OpenAlex ID: A5133890531
Nivolumab and Ipilimumab Combination Treatment in Patients with Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: Results from the Phase II MoST-CIRCUIT Trial
2026 · Adnan Nagrial, Matteo S. Carlino, et al. · Clinical Cancer Research · 4
Data from Nivolumab and Ipilimumab Combination Treatment in Patients with Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: Results from the Phase II MoST-CIRCUIT Trial
2026 · Adnan Nagrial, Matteo S. Carlino, et al.
Supplementary Table S1 from Nivolumab and Ipilimumab Combination Treatment in Patients with Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: Results from the Phase II MoST-CIRCUIT Trial
2026 · Adnan Nagrial, Matteo S. Carlino, et al.
Abstract CT304: Narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial) a Phase 1b 2a study-Interim analysis
2026 · Terrie-Anne Cock, Sumitra Ananda, et al. · Cancer Research
Works count: 4
Citation count: 4
H-index: 1
I10-index:
Year
Topic
Type
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms